Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Crispr Therapeutics AGTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Zimmer Biomet Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.5× Crispr Therapeutics AG's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPZBH
Market Cap
$5.23B$18.55B
Sector
HealthHealth
52-Week High
$76.78$107.71
52-Week Low
$44.34$79.58
Enterprise Value
$3.65B$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.

The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH